Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Tranexamic acid (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein. It has been utilized in angiotensin converting enzyme (ACE) inhibitor-induced angioedema (ACEi-AE) in small case reports and series however overall data is limited. This report describes a patient who historically received TXA for ACEi-AE and represented with ACEi-AE after an accidental exposure and was successfully treated with TXA again. This case suggests TXA may be a safe and effective treatment option for ACEi-AE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajem.2022.01.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Total blood loss and early clinical outcomes under different Tranexamic acid regimes in total knee arthroplasty.
Arch Orthop Trauma Surg
September 2025
Department of Orthopaedic Surgery, Koenig-Ludwig-Haus, University of Wuerzburg, Brettreichstr. 11,, 97074, Wuerzburg, Germany.
Randomized Clinical Trial on the Efficacy of Oral Tranexamic Acid Versus Topical Tranexamic Acid in Treatment of Melasma.
J Cosmet Dermatol
September 2025
Department of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran.
Background: Melasma is a prevalent skin condition that primarily affects females of reproductive age. Despite the various available treatments, managing melasma is challenging due to frequent relapses and partial responses. Tranexamic acid (TXA) has gained attention as a potential treatment because of its antifibrinolytic and anti-melanogenic properties.
View Article and Find Full Text PDFEnolase-1 Is a Key Regulator of Neutrophil Recruitment During Acute Inflammation.
Immunology
September 2025
Department of Biochemical Science and Technology, National Taiwan University, Taipei, Taiwan, ROC.
Enolase-1 (ENO1) is a moonlighting protein with multiple functions. When expressed on the cell surface, ENO1 binds plasminogen (PLG) and promotes cell migration by facilitating plasmin (PLM)-mediated extracellular matrix degradation. Here, we observed that inflammatory stimulation significantly upregulated ENO1 expression on the neutrophil surface, both in vitro and in vivo.
View Article and Find Full Text PDFThromboembolic safety and clinical benefits of tranexamic acid beyond hemostasis in post-COVID-19 patients undergoing major arthroplasty: A STROBE-compliant retrospective study.
Medicine (Baltimore)
September 2025
Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan.
The safety of tranexamic acid (TXA) in patients with recent coronavirus disease (COVID-19) infection undergoing major arthroplasty remains unclear. We aimed to evaluate whether TXA increases thromboembolic risk in post-COVID-19 patients undergoing major arthroplasty. Using the TriNetX database, we identified patients aged ≥50 years who underwent total knee or hip arthroplasty with documented COVID-19 within 3 months prior to surgery.
View Article and Find Full Text PDFSwelling Management in Total Knee Arthroplasty: A Systematic Review.
JBJS Rev
September 2025
Joondalup Health Campus, Joondalup, Australia.
Background: Postoperative swelling is a common complication after total knee arthroplasty (TKA), associated with pain, limited mobility, and delayed recovery. This study aimed to systematically review the literature on interventions that reduce postoperative swelling, categorized into preoperative, intraoperative, and postoperative phases.
Methods: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant search of PubMed, Medline, Embase, and Cochrane databases was performed for clinical studies evaluating interventions to reduce swelling after primary TKA.